Skip to main content

Table 1 Basic general and oncological characteristics according to state of postoperative Tyrosinkinase Inhibitor (TKI) therapy

From: The value of hepatic resection in metastasic renal cancer in the Era of Tyrosinkinase Inhibitor Therapy

Variables Overall (n = 35) TKI (+) (n = 16) TKI (-) (n = 19) p-value
Median Age (years) 65 (59–71) 64.5 (58–71) 69 (62–71) 0.160a
Gender 24:11 12:4 12:7 0.452d
 Male/female (68.6/31.4 %) (34.3:11.4 %) (34.3:20 %)  
Median Body mass index (kg/m2) 26.5 (24.5–28.0) 26.9 (26.0–28.3) 25.9 (24.2–27.7) 0.349a
ECOG performance status (%)
 0 29 (82.9 %) 15 (42.9 %) 14 (40 %) 0.117d
 1 6 (17.1 %) 1 (2.9 %) 5 (14.3 %)  
Primary tumor characteristics
 Right side/left side; n (%) 21/14 (60 %:40 %) 7/9 (20 %:25.7 %) 14/5 (40 %:14.3) 0.072d
Primary tumor histology
 Clear cell 25 (71.4 %) 10 (28.6 %) 15 (42.9 %) 0.283c
 Non-clear cell 10 (28.6 %) 6 (17.1 %) 4 (11.5 %)  
Primary tumor T-stage
 Stage 1–2 16 (45.8 %) 8 (22.9 %) 8 (22.9 %) 0.640c
 Stage 3–4 19 (54.2 %) 11 (31.3 %) 8 (22.9 %)  
Primary tumor grading
 Low (Fuhrmann 1–2) 24 (68.6 %) 12 (34.3 %) 12 (34.3 %) 0.452d
 High (Fuhrmann 3–4) 11 (31.4 %) 4 (11.4 %) 7 (20 %)  
Liver tumor distribution
 Unilobular/Multilobular 28:7 (80 %:20 %) 14:2 (40 %:14.3 %) 14:5 (40 %:5.7 %) 0.309d
Median tumor size (cm) 4.4 (2.9–6.0) 3.9 (2.5–4.5) 5.6 (3.0–7.5) 0.094a
Mean number of hepatic tumor lesions 1.70 (1–5) 1.64 (1–4) 1.74 (1–5) 0.813b
Median weight of resected liver (g) 212.5 (39.2–652.5) 81.4 (15.5–265.0) 290 (70–916.3) 0.138a
Timing of liver metastases
 Synchronous/ 6 (17.1 %) 4 (11.4 %) 2 (5.7 %) 0.258d
 metachronous 29 (82.9 %) 12 (34.3) 17 (48.6 %)  
Extrahepatic disease at time of liver-directed therapy
 Yes 7 (20 %) 5 (14.3 %) 2 (5.7 %) 0.127d
 No 28 (80 %) 11 (31.4 %) 17 (48.6 %)  
  1. Used statistical tests:
  2. aStudent’s t-test
  3. bWilcoxon rank sum test
  4. cchi-squared test
  5. dFisher’s exact test